Ranolazine IV-to-Oral Transition for Acute Cardiovascular Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a method to rapidly stabilize patients with acute cardiovascular disease events, particularly those with non-ST elevation acute coronary syndrome, and to maintain their stability over an extended period using a combination of intravenous and oral ranolazine formulations.
Innovation Solution
The method involves administering an intravenous solution of ranolazine at selected concentrations, titrating the dosage to achieve therapeutic plasma levels, and transitioning to an oral sustained release formulation once the patient is stabilized, with specific dosing regimens and excipient compositions to ensure effective and safe delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If intravenous ranolazine is administered at high concentration to rapidly stabilize patients with acute cardiovascular disease events, then the speed of stabilization is improved, but the risk of adverse effects and toxicity increases
Solution Approach 1:
The patent applies parameter changes by titrating the intravenous ranolazine infusion rate and adjusting the concentration based on patient response and serum levels. The infusion starts at a lower rate (e.g., 200 mg/hr) and can be adjusted upward or downward based on clinical effectiveness and tolerance, thereby achieving rapid stabilization while minimizing adverse effects through controlled parameter adjustment.
Solution Approach 2:
The patent implements feedback mechanisms by monitoring serum ranolazine concentrations and patient response to guide dose adjustments. The dosing regimen is modified based on observed effectiveness and adverse effects, allowing the system to self-regulate and optimize the balance between rapid stabilization and safety.
2Productivity
If intravenous ranolazine is administered to rapidly treat acute cardiovascular disease events, then the productivity of treatment is improved, but the complexity of dosing regimen increases
Solution Approach 1:
The patent segments the treatment process into distinct phases: an initial intravenous infusion phase for rapid stabilization, followed by a transition to oral formulation for maintenance therapy. This segmentation allows the complex dosing to be managed in manageable stages, with clear criteria for transitioning from IV to oral administration, thereby improving productivity while controlling complexity.
Solution Approach 2:
The patent applies dynamics by making the dosing regimen adaptable rather than fixed. The intravenous infusion rate and duration are dynamically adjusted based on patient response, serum levels, and clinical status, allowing the treatment to optimize productivity for each individual patient while managing complexity through flexible rather than rigid protocols.
3Duration of action of moving object
If intravenous ranolazine is used to stabilize patients acutely, then the duration of acute stabilization is improved, but the loss of time for transition to oral formulation increases
Solution Approach 1:
The patent applies preliminary action by initiating the transition to oral formulation before the intravenous infusion is completely discontinued. The oral medication is started at a lower dose during the IV infusion, and the IV rate is gradually reduced, allowing for a seamless transition that minimizes time loss while maintaining adequate stabilization duration.
Solution Approach 2:
The patent ensures continuity of useful action by overlapping the IV and oral administration periods. The oral formulation is introduced during the IV infusion, and the IV rate is progressively reduced rather than abruptly stopped, maintaining continuous therapeutic effect and minimizing the time loss associated with transition while preserving adequate stabilization duration.
Data Source
AI summary
Disclosed is the treatment of patients suffering from cardiovascular diseases with an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.